CYSTAGON Drug Patent Profile

« Back to Dashboard

When do Cystagon patents expire, and what generic alternatives are available?

Cystagon is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in CYSTAGON is cysteamine bitartrate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cysteamine bitartrate profile page.

Summary for CYSTAGON

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	11
Drug Prices:	Drug price information for CYSTAGON
What excipients (inactive ingredients) are in CYSTAGON?	CYSTAGON excipients list
DailyMed Link:	CYSTAGON at DailyMed

See drug prices for CYSTAGON

Recent Clinical Trials for CYSTAGON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nacuity Pharmaceuticals, Inc.	Phase 1/Phase 2
University of Huddersfield	Phase 1/Phase 2
NHS Grampian	Phase 1/Phase 2

See all CYSTAGON clinical trials

Pharmacology for CYSTAGON

Drug Class	Cystine Depleting Agent
Mechanism of Action	Cystine Disulfide Reduction

US Patents and Regulatory Information for CYSTAGON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	CYSTAGON	cysteamine bitartrate	CAPSULE;ORAL	020392-001	Aug 15, 1994		RX	Yes	No
Mylan	CYSTAGON	cysteamine bitartrate	CAPSULE;ORAL	020392-002	Aug 15, 1994		RX	Yes	Yes

Cystagon Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook

Last updated: September 24, 2026

Cystagon is an established immediate-release cysteamine bitartrate therapy for nephropathic cystinosis. Its market is defined by a very small patient population, lifelong treatment, high dosing frequency, limited therapeutic substitutes, and competition from delayed-release Procysbi. Cystagon has no meaningful new-drug exclusivity remaining, and its core active-ingredient protection is long expired. Product-level revenue is not publicly disclosed, so the financial analysis relies on market structure, patient economics, regulatory records, and competitor disclosures rather than audited Cystagon sales.

What is Cystagon and what disease does it treat?

Cystagon is an oral cysteamine bitartrate product used to reduce cystine accumulation in patients with nephropathic cystinosis. Cystinosis is a rare lysosomal storage disorder caused by mutations in the CTNS gene. Cysteamine depletes intracellular cystine and delays progression of renal and extrarenal disease when treatment is maintained over a patient’s lifetime.

The FDA approved Cystagon under NDA 020392 in 1994. The product is supplied as immediate-release capsules in 50 mg and 150 mg strengths. The labeled maintenance dose is generally based on body-surface area and is divided into four daily administrations, creating a demanding adherence schedule for pediatric and adult patients [1].

Cystagon product profile

Attribute	Cystagon
Active ingredient	Cysteamine bitartrate
Dosage form	Immediate-release oral capsules
FDA NDA	020392
Initial U.S. approval	1994
Primary indication	Nephropathic cystinosis
Typical dosing frequency	Four times daily
Capsule strengths	50 mg and 150 mg
Disease population	Ultra-rare, lifelong treatment
Regulatory status	Approved drug
Biosimilar relevance	None
Core composition patent status	Expired

Cystagon is pharmacologically differentiated from cysteamine ophthalmic products. Cystaran, for example, is an ophthalmic cysteamine hydrochloride product used to treat corneal cystine crystal accumulation. Cystaran does not substitute for systemic Cystagon therapy.

How large is the Cystagon market?

The addressable market is small in patient count but potentially substantial in revenue per treated patient. Published estimates generally place the worldwide cystinosis population in the low thousands or below, with the United States representing a few hundred diagnosed patients rather than a mass-market population [2,3].

The commercial market has four structural characteristics:

1. Treatment is chronic and begins frequently in childhood.
2. Therapy is clinically important because untreated cystinosis causes progressive kidney and multisystem damage.
3. Cystagon has a low patient volume, which limits manufacturing scale and generic competition.
4. The annual cost per patient can be high relative to conventional generic medicines, particularly in the United States.

No public filing provides a reliable, standalone global revenue figure for Cystagon. Manufacturers generally report rare-disease products within broader portfolios or geographic segments. That prevents a definitive calculation of Cystagon’s annual sales, gross margin, or year-by-year revenue growth.

What drives Cystagon demand?

Demand is driven primarily by diagnosed prevalence, treatment initiation, patient survival, and adherence rather than by broad physician promotion. Population growth is limited because cystinosis remains ultra-rare. Revenue growth therefore depends more on:

• Price increases;
• Geographic expansion;
• Improved diagnosis;
• Patient retention;
• Higher survival into adulthood;
• Distribution and reimbursement access;
• Product switching within cysteamine therapy.

The market has relatively low volume elasticity. Patients cannot readily discontinue treatment without increasing the risk of disease progression. This gives an established supplier greater pricing power than a conventional generic manufacturer, although payer controls and alternative cysteamine products constrain that power.

What is the financial trajectory of Cystagon?

Cystagon’s financial trajectory is best characterized as mature, defensive, and patient-value driven rather than volume driven. The product’s revenue base is supported by chronic use and a narrow clinical indication, but it lacks the exclusivity-driven growth profile of a newly launched orphan drug.

Revenue visibility

Public companies associated with cysteamine products have generally disclosed franchise-level or corporate revenue rather than Cystagon-specific sales. The available public record does not support a verified annual Cystagon revenue series.

Financial variable	Public visibility
Cystagon annual net sales	Not separately disclosed
Net price by payer	Not publicly standardized
U.S. patient count	Not consistently disclosed by product
Gross margin	Not disclosed
Product-level operating profit	Not disclosed
R&D spending dedicated to Cystagon	Not disclosed
Global sales by country	Not disclosed

This lack of disclosure is common for mature orphan products. A product can remain commercially valuable without producing a material percentage of the parent company’s consolidated revenue.

Revenue scenarios

Cystagon’s future revenue is likely to follow one of three paths:

Scenario	Main drivers	Expected commercial effect
Stable mature franchise	Persistent treatment, limited substitution, stable reimbursement	Low-single-digit or flat nominal growth
Price-led growth	Annual price increases exceed unit decline	Revenue growth without major patient expansion
Erosion scenario	Generic entry, payer substitution, supply disruption, or switching to Procysbi	Declining volume and lower pricing power

A sharp patient-volume increase is unlikely because the underlying disease population is small. The more important risk is share migration to delayed-release cysteamine products, particularly among patients who have difficulty maintaining four-times-daily immediate-release dosing.

When does Cystagon lose exclusivity?

Cystagon has already lost its principal regulatory and patent exclusivity.

FDA exclusivity

Cystagon’s 1994 approval predates the modern commercial importance of orphan-drug exclusivity, and any original regulatory exclusivity has expired. FDA orphan-drug exclusivity lasts seven years from approval under the Orphan Drug Act, subject to statutory conditions. That period is not renewable merely because the product remains clinically important [4].

Cystagon also is not protected by new chemical entity exclusivity. Cysteamine is an old active ingredient, and Cystagon’s commercial value comes from formulation, regulatory approval, manufacturing, and market position rather than chemical novelty.

Patent expiration

The core cysteamine bitartrate composition is based on an old active ingredient. Any patents covering the original product or basic use of cysteamine would have expired long ago. The commercial question is therefore not whether Cystagon has an active core patent. It is whether a later patent covers a specific formulation, manufacturing process, package, or method of use.

The FDA Orange Book is the principal source for patents submitted by NDA holders for approved drug products. A review of the Cystagon NDA record does not indicate an active patent estate comparable to the later patent portfolio associated with delayed-release cysteamine products [5].

What is the Orange Book status of Cystagon?

Cystagon is an approved NDA product, but its commercial protection is materially weaker than that of a recently approved specialty drug.

Orange Book issue	Cystagon position
Approved NDA	Yes, NDA 020392
Active ingredient protection	No
New chemical entity exclusivity	No
Original orphan exclusivity	Expired
Core product patents	Expired or not commercially controlling
Paragraph IV exposure	Possible if an ANDA targets the product
30-month stay risk	Dependent on any qualifying listed patent
Authorized generic risk	Relevant if a generic arrangement is established

An ANDA applicant seeking approval for cysteamine bitartrate capsules could use a Paragraph III certification if a listed patent remains unexpired or a Paragraph IV certification if the applicant challenges a listed patent. Because the central Cystagon protection is old, the most likely barriers are regulatory, technical, manufacturing, and commercial rather than a strong blocking patent.

Which companies are challenging Cystagon?

There is no major, publicly visible Paragraph IV litigation campaign against Cystagon comparable to the litigation surrounding larger specialty drugs. The absence of prominent litigation does not mean that generic entry is impossible. It indicates that the expected commercial return may not justify the cost of developing, validating, launching, and distributing an ultra-rare-disease product.

Potential challengers include:

• Generic drug companies with established capsule manufacturing;
• Specialty pharmaceutical companies seeking rare-disease products;
• Regional suppliers in markets where Cystagon is sold through hospital or specialty channels;
• Companies using cysteamine as a platform for new oral or topical formulations.

Why generic entry may be slow

Cystagon’s low patient volume can weaken the business case for an ANDA despite the absence of strong patent protection. A challenger must manage:

• Bioequivalence and product-quality requirements;
• Low manufacturing scale;
• Pediatric dosing requirements;
• Specialty pharmacy distribution;
• Patient and physician switching;
• Reimbursement contracting;
• Supply continuity expectations;
• Pharmacovigilance in a small patient population.

For an ultra-rare drug, a generic competitor may need substantial market share to recover development and launch costs. This creates a practical barrier that can persist after legal exclusivity expires.

What formulations are protected in the cysteamine market?

The principal formulation distinction is between immediate-release and delayed-release cysteamine.

Cystagon immediate-release formulation

Cystagon is an immediate-release capsule taken multiple times daily. Its advantages include:

• Long clinical experience;
• Established dosing practice;
• Familiarity among cystinosis specialists;
• Lower formulation complexity than delayed-release products;
• A broad historical treatment base.

Its main disadvantage is the dosing burden. Four-times-daily dosing can interfere with school, work, sleep, travel, and adherence.

Procysbi delayed-release formulation

Procysbi is a delayed-release cysteamine bitartrate product approved by the FDA in 2013. It was developed to reduce dosing frequency and improve tolerability and adherence. Its formulation and method-of-use patents have provided a stronger period of commercial protection than the original Cystagon product [6,7].

Product	Release profile	Typical dosing burden	Strategic position
Cystagon	Immediate release	Four times daily	Established, lower-complexity therapy
Procysbi	Delayed release	Generally twice daily	Premium differentiated formulation
Cystaran	Ophthalmic solution	Eye administration	Corneal disease, not systemic replacement

Procysbi creates the most important commercial pressure on Cystagon. The competitive decision is not simply brand versus generic. It is also immediate-release versus delayed-release delivery.

How does Cystagon compare with Procysbi?

Factor	Cystagon	Procysbi
Approval era	1994	2013
Formulation	Immediate release	Delayed release
Dosing frequency	Four times daily	Generally twice daily
Patient convenience	Lower	Higher
Patent position	Mature and limited	Stronger formulation and method protection during its protected period
Likely price position	Lower or more established	Premium
Switching risk	Risk of migration to Procysbi	Risk from cost controls and future generic entry
Main commercial asset	Installed patient base	Adherence and formulation differentiation

Cystagon can retain patients when physicians prioritize clinical familiarity, access, and cost. Procysbi is better positioned when adherence, gastrointestinal tolerability, and reduced dosing frequency justify a higher price.

What patent litigation affects the cysteamine market?

The major patent risk in the cysteamine market has historically centered on delayed-release products rather than the original Cystagon formulation. Patents covering Procysbi-related formulations and dosing methods have been more commercially significant than patents covering Cystagon itself.

The litigation risk profile has several layers:

1. A generic applicant may challenge patents listed for a delayed-release product.
2. A brand company may assert formulation or method-of-use patents.
3. Courts may narrow claims based on obviousness, written description, enablement, or claim construction.
4. Settlement agreements may delay generic launch while preserving a later market-entry date.
5. Cystagon may face indirect erosion if patients switch to a competing protected formulation rather than to a generic equivalent.

No publicly established settlement is identified here as controlling Cystagon’s immediate-release capsule market. The commercial impact of delayed-release litigation is nevertheless relevant because it affects the timing and cost of switching between cysteamine products.

What is the FDA regulatory status of Cystagon?

Cystagon remains an FDA-approved prescription product for nephropathic cystinosis. Its regulatory value is tied to the existing NDA, labeling, safety history, and specialist use rather than to active regulatory exclusivity.

The key FDA-related risks are:

• Manufacturing compliance;
• Product supply;
• Capsule dissolution and quality consistency;
• Labeling changes;
• Pediatric dosing and safety monitoring;
• Postmarketing adverse-event obligations;
• Import or distribution interruptions.

For an old orphan product, regulatory compliance can be a more immediate business risk than patent validity. A small patient population makes shortages highly visible and difficult to offset with alternative inventory.

How strong is the Cystagon patent estate?

Cystagon’s patent estate is weak as a standalone blocking position. The product has several non-patent advantages that can still support commercial durability.

Protection category	Strength
Active ingredient patent	None of practical significance
Original product patent	Expired
Orphan exclusivity	Expired
Formulation patent	Limited for the original immediate-release product
Method-of-use protection	Limited relative to newer products
Regulatory know-how	Moderate
Physician familiarity	Moderate to strong
Patient continuity	Strong
Manufacturing and supply reliability	Commercially important
Distribution relationships	Important in rare disease

The overall estate is therefore legally weak but commercially resilient. The distinction matters for valuation. Cystagon should not be valued as a patent-protected growth asset. It is better analyzed as a mature specialty franchise with switching costs and recurring demand.

What generic launch risks exist for Cystagon?

A generic Cystagon launch could produce gradual rather than immediate erosion.

Likely launch effects

A first generic could:

• Reduce reimbursement for the immediate-release segment;
• Trigger pharmacy-level substitution where legally permitted;
• Pressure the brand’s net price;
• Increase payer use of prior authorization and preferred-product rules;
• Cause patients to move among immediate-release suppliers;
• Preserve some brand volume through physician and patient preference.

The impact would depend on the generic’s status as therapeutically equivalent, its manufacturing reliability, payer coverage, and whether Cystagon remains available through specialty distribution.

Generic versus Procysbi risk

Generic Cystagon and Procysbi create different risks:

Risk source	Effect on Cystagon
Immediate-release generic	Price and share erosion
Procysbi switching	Patient-volume erosion with possible premium-product migration
Cysteamine shortage	Temporary demand disruption and reputational damage
New delivery technology	Long-term displacement risk
Payer policy	Accelerated substitution or restricted access

What geographic markets matter for Cystagon?

The United States is likely the most commercially important market because orphan-drug pricing and specialty reimbursement can support high annual revenue per patient. Europe has a more fragmented reimbursement environment, with national pricing and health-technology assessment processes influencing access.

Geographic risk varies by market:

• United States: greater pricing potential, but higher payer scrutiny and patent litigation exposure.
• European Union: broader centralized regulatory context but country-level reimbursement pressure.
• United Kingdom: National Health Service budget controls and formal cost-effectiveness considerations.
• Emerging markets: lower prices and more limited diagnostic infrastructure, but potential underdiagnosis creates long-term expansion opportunity.

Cystagon’s global growth depends less on large-volume penetration than on reliable diagnosis, specialist access, and uninterrupted supply.

What manufacturing and intellectual-property barriers protect Cystagon?

Manufacturing barriers are more important than patent barriers. Cysteamine products require consistent quality, appropriate capsule performance, stability control, packaging, and reliable supply for a lifelong-use population.

The main operational barriers include:

• Sourcing pharmaceutical-grade cysteamine;
• Managing odor and handling characteristics;
• Maintaining capsule stability;
• Validating dissolution and release performance;
• Producing multiple pediatric-relevant strengths;
• Supporting small-batch production economically;
• Maintaining specialty distribution.

These factors can deter small generic entrants, but they do not provide the same legal exclusivity as a valid patent. A well-capitalized generic company with established capsule infrastructure could overcome them.

What is the outlook for Cystagon revenue?

Cystagon revenue is likely to remain relatively stable if the product retains its installed base and avoids supply disruption. The most credible downside drivers are generic entry, payer-led substitution, and migration to Procysbi. The strongest support factors are lifelong treatment, clinical familiarity, and the limited size of the patient pool.

The product’s financial trajectory can be summarized as follows:

• Near term: recurring demand with limited patient growth.
• Medium term: pricing and share pressure if immediate-release generics enter.
• Longer term: gradual erosion from alternative formulations and improved delivery systems.
• Valuation implication: recurring specialty cash flow, but limited patent-based terminal value.

Key Takeaways

• Cystagon is an FDA-approved immediate-release cysteamine bitartrate product for nephropathic cystinosis.
• Its original regulatory and patent exclusivity has expired.
• No meaningful Cystagon-specific revenue series is publicly disclosed.
• The market is small, chronic, and commercially durable because patients require lifelong therapy.
• Procysbi is the principal branded competitive threat because of delayed release and lower dosing frequency.
• A generic launch would likely create price pressure, but ultra-rare-disease economics can delay entry.
• Cystagon’s strongest defenses are patient continuity, physician familiarity, supply reliability, and specialty distribution.
• The product should be valued as a mature rare-disease franchise, not as an actively patent-protected growth asset.
• Manufacturing and distribution barriers are more important than the original Cystagon patent estate.
• The largest financial risks are generic substitution, Procysbi switching, payer controls, and supply interruption.

FAQs

Is Cystagon still available in the United States?

Cystagon remains an FDA-approved prescription therapy for nephropathic cystinosis. Commercial availability can vary by manufacturer, distributor, and specialty pharmacy supply.

Is Cystagon the same as Procysbi?

No. Both contain cysteamine bitartrate, but Cystagon is an immediate-release capsule and Procysbi is a delayed-release formulation designed for less frequent dosing.

Does Cystagon have orphan-drug exclusivity today?

No. Any original orphan-drug exclusivity associated with its approval has expired.

Can a generic manufacturer launch cysteamine bitartrate capsules?

Potentially. The principal barriers are regulatory approval, manufacturing economics, specialty distribution, bioequivalence, and the small patient population rather than a strong active patent blocking the original product.

Is Cystaran a substitute for Cystagon?

No. Cystaran is an ophthalmic cysteamine product for corneal cystine crystals. It does not replace systemic cysteamine therapy for nephropathic cystinosis.

References

1. U.S. Food and Drug Administration. (2018). Cystagon (cysteamine bitartrate) capsules: Prescribing information. FDA.

2. Elmonem, M. A., Venselaar, H., Soliman, N. A., van der Kemp, A. W. C. M., & Elmonem, M. A. (2016). Cystinosis: A review. Orphanet Journal of Rare Diseases, 11, 47.

3. Nesterova, G., & Gahl, W. A. (2017). Nephropathic cystinosis: Late complications of a multisystemic disease. Pediatric Nephrology, 32, 769-776.

4. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Food and Drug Administration. (2013). Procysbi (cysteamine bitartrate) delayed-release capsules: Approval letter and prescribing information. FDA.

7. Chiesi Farmaceutici S.p.A. (2023). Annual report and financial disclosures. Chiesi Farmaceutici.